@article{11193,
  keywords = {Humans, *Diabetes Mellitus, Type 2/epidemiology/drug therapy, *Electronic Health Records/statistics & numerical data, Female, Male, *Machine Learning, Middle Aged, Prognosis, Aged, Adult, Hypoglycemic Agents/therapeutic use, Incidence, Follow-Up Studies, diabetes mellitus, type 2, Electronic Health Records, epidemiology, Informatics, biopharmaceutical company, and declare stock and stock options. AB has received, research funding from AstraZeneca. KK has acted as a consultant, speaker or, received grants for investigator-initiated studies for AstraZeneca, Bayer,, Novartis, Novo Nordisk, Sanofi-Aventis, Lilly and Merck Sharp & Dohme, Boehringer, Ingelheim, Oramed Pharmaceuticals, Roche and Applied Therapeutics.},
  author = {M. Mizani and A. Dashtban and L. Pasea and Q. Zeng and K. Khunti and J. Valabhji and J. Mamza and H. Gao and T. Morris and A. Banerjee},
  title = {Identifying subtypes of type 2 diabetes mellitus with machine learning: development, internal validation, prognostic validation and medication burden in linked electronic health records in 420 448 individuals},
  year = {2024},
  journal = {BMJ Open Diabetes Res Care},
  volume = {12},
  edition = {2024/06/05},
  number = {3},
  isbn = {2052-4897},
  doi = {10.1136/bmjdrc-2024-004191},
  note = {2052-4897
Mizani, Mehrdad A
Orcid: 0000-0002-2441-895x
Dashtban, Ashkan
Pasea, Laura
Zeng, Qingjia
Khunti, Kamlesh
Valabhji, Jonathan
Mamza, Jil Billy
Gao, He
Orcid: 0000-0001-7764-198x
Morris, Tamsin
Banerjee, Amitava
Orcid: 0000-0001-8741-3411
Journal Article
Validation Study
England
BMJ Open Diabetes Res Care. 2024 Jun 4;12(3):e004191. doi: 10.1136/bmjdrc-2024-004191.},
  language = {eng},
}